TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8667183

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.125 mg/70 kg i.v.)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fentanyl (0.25 mg/70 kg i.v.)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Alfentanil (1 mg/70 kg i.v.)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Alfentanil (2 mg/70 kg i.v.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg/70 kg i.m.)
Number of subjects: 2
Study: 1641432

Group type: EXPERIMENTAL
Intervention: Cost subsidy, mammography van, and tailored health education interventions
Number of subjects: 412

Group type: COMPARATOR
Intervention: Cost subsidy alone (Control)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Attendance at the educational presentation (within experimental group)
Number of subjects: 412
Study: 6197239

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 136
Study: 30726224

Group type: EXPERIMENTAL
Intervention: Single-dose sulfadoxine-pyrimethamine (SP) and 3 doses of amodiaquine (AQ) every three months
Number of subjects: 206
Study: 29024410

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily (OD) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg OD for 8 weeks
Number of subjects: 60
Study: 26743775

Group type: EXPERIMENTAL
Intervention: 100 µg glucagon
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 µg glucagon
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 300 µg glucagon
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 24601909

Group type: EXPERIMENTAL
Intervention: Managers choosing a new alternative versus familiar alternative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High risk takers versus low risk takers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision makers opposing others' advice by choosing high risk option
Number of subjects: 0
Study: 22974886

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (3 mg/kg/d; group A)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fluconazole (800 mg loading dose and thereafter 400 mg/d; group B)
Number of subjects: 44
Study: 20102150

Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 30 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 50 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 0.1 mg/kg, i.v.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWJ-671818 at 1.0 mg/kg, i.v.
Number of subjects: 0
Study: 16935912

Group type: EXPERIMENTAL
Intervention: Abatacept 2 mg/kg during double-blind phase
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Abatacept 10 mg/kg during LTE
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Abatacept and etanercept
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo and etanercept
Number of subjects: 121
Study: 16970088

Group type: EXPERIMENTAL
Intervention: ETR plus FSH
Number of subjects: 66

Group type: COMPARATOR
Intervention: FSH alone
Number of subjects: 66
Study: 12211346

Group type: EXPERIMENTAL
Intervention: Intelligent decision support systems
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10474785

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study: 8714425

Group type: EXPERIMENTAL
Intervention: Yohimbine 15 mg daily for 7 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Yohimbine 15 mg daily
Number of subjects: 31
Study: 1927727

Group type: EXPERIMENTAL
Intervention: Health education programme emphasizing healthy diet, non-smoking encouragement, and physical activity for 281 pupils.
Number of subjects: 521

Group type: COMPARATOR
Intervention: Control group (240 pupils who did not participate in the programme).
Number of subjects: 521
Study: 6336944

Group type: EXPERIMENTAL
Intervention: Retinoid therapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clinically involved psoriatic epidermis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Uninvolved skin of the same patients
Number of subjects: 8
Study: 31640921

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rigid immobilization
Number of subjects: 21
Study: 31517964

Group type: EXPERIMENTAL
Intervention: Prize-linked savings accounts with 1000 Kenya shillings (US 10) and weekly lottery-based rewards contingent on growth in savings balance
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard interest savings accounts
Number of subjects: 300
Study: 27695925

Group type: EXPERIMENTAL
Intervention: Coaxial method
Number of subjects: 166

Group type: COMPARATOR
Intervention: Noncoaxial method
Number of subjects: 166
Study: 26523919

Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg twice daily
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg twice daily
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg twice daily
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate 1 mg/d
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1254
Study: 24680227

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT), 16-20 sessions over 12-14 weeks
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 473
Study: 22976847

Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TNE)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Sedated endoscopy (SES)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Conventional endoscopy (CES)
Number of subjects: 397
Study: 19574169

Group type: EXPERIMENTAL
Intervention: 24-hour urinary protein measurement
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 24-hour urinary calcium measurement
Number of subjects: 200
Study: 17888019

Group type: EXPERIMENTAL
Intervention: Immediate implant placement in extraction sockets exhibiting periapical pathology (test group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Immediate implant placement in extraction sockets without periapical pathology (control group)
Number of subjects: 34
Study: 15130377

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) alone, Group A
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rosiglitazone alone, Group B
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) and rosiglitazone in combination, Group C
Number of subjects: 96
Study: 11404757

Group type: EXPERIMENTAL
Intervention: Primer + adhesive group (PA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Primer‐only group (PO)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (etched Lp = ELp)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Impression Lp (ILp)
Number of subjects: 80
Study: 9646215

Group type: EXPERIMENTAL
Intervention: Nutrilon AR formula
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional thickened formula (5% rice flour)
Number of subjects: 24
Study: 7962674

Group type: EXPERIMENTAL
Intervention: Ketorolac 15 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2871378

Group type: EXPERIMENTAL
Intervention: Nd-YAG laser photocoagulation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (no laser treatment)
Number of subjects: 138
Study: 31603778

Group type: EXPERIMENTAL
Intervention: Source Density Apodisation (SDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amplitude Apodisation (AmpA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asymmetric SDA schemes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-smoothly varying spatial source density
Number of subjects: 0
Study: 29300259

Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy for urgency-predominant urinary incontinence
Number of subjects: 640

Group type: COMPARATOR
Intervention: Sleeping medications (used by 13% of participants 3 or more times per week)
Number of subjects: 640
Study: 27017403

Group type: COMPARATOR
Intervention: Interferential current stimulation (IFCS) applied to submandibular and sublingual glands.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no IFCS).
Number of subjects: 60
Study: 25326710

Group type: EXPERIMENTAL
Intervention: All Children in Focus program (intervention group)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 621
Study: 23685640

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (n = 215), 0.5 mEq/kg/hr for the first hour and then 0.2 mmol/kg/hr for 23 hours
Number of subjects: 427

Group type: COMPARATOR
Intervention: Sodium chloride infusion (n = 212)
Number of subjects: 427
Study: 20941936

Group type: EXPERIMENTAL
Intervention: Early rehabilitation starting from the first postoperative day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with rehabilitation starting 3 weeks after surgery
Number of subjects: 60
Study: 18258532

Group type: EXPERIMENTAL
Intervention: Epiclose‐T device
Number of subjects: 71

Group type: COMPARATOR
Intervention: Manual compression (Control)
Number of subjects: 71
Study: 16365063

Group type: EXPERIMENTAL
Intervention: 3 g ALA/d from flaxseed oil capsules
Number of subjects: 56

Group type: COMPARATOR
Intervention: Olive oil placebo capsules
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Flaxseed oil and Olive oil
Number of subjects: 56
Study: 12565986

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (r-HuEPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11038148

Group type: EXPERIMENTAL
Intervention: Low dose Iloprost (50-100 microgram twice a day)
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: High dose Iloprost (150-200 microgram twice a day)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study: 9101938

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted resections
Number of subjects: 39
Study: 1358139

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classical antihistamines
Number of subjects: 0
Study: 6787910

Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 20
Study: 30540660

Group type: EXPERIMENTAL
Intervention: Laparoscopic transversus abdominis plane block
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane block
Number of subjects: 107

Group type: COMPARATOR
Intervention: No transversus abdominis plane block
Number of subjects: 107
Study: 29197338

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.375%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75%
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ropivacaine (all concentrations)
Number of subjects: 78
Study: 25360863

Group type: EXPERIMENTAL
Intervention: Balloon dilation of the frontal sinus drainage pathway
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional frontal sinusotomy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balloon dilation
Number of subjects: 30
Study: 23643848

Group type: EXPERIMENTAL
Intervention: Desensitising paste containing 8% arginine and calcium carbonate (Ar‐Ca)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pumice treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 0
Study: 21233431

Group type: EXPERIMENTAL
Intervention: Integrated behavioral intervention
Number of subjects: 436

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 436
Study: 19188061

Group type: EXPERIMENTAL
Intervention: Glufosfamide plus best supportive care (BSC)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 303
Study: 17519792

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CNI)
Number of subjects: 40
Study: 16638294

Group type: EXPERIMENTAL
Intervention: Sequential MV group (n = 47)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional MV group (n = 43)
Number of subjects: 90
Study: 14640819

Group type: EXPERIMENTAL
Intervention: Variable practice
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Self-efficacy generality
Number of subjects: 82

Group type: COMPARATOR
Intervention: Constant practice
Number of subjects: 82
Study: 10483953

Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 85

Group type: COMPARATOR
Intervention: PTCA alone (no further intervention)
Number of subjects: 85
Study: 8954038

Group type: EXPERIMENTAL
Intervention: Hexarelin (1.0 microgram/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hexarelin (0.5 microgram/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GHRH-(1-29)-NH2 (1.0 microgram/kg) + Hexarelin (0.125 microgram/kg)
Number of subjects: 0
Study: 1673977

Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 0.5 mg nebulized aerosol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of Terfenadine and Ipratropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6460207

Group type: EXPERIMENTAL
Intervention: Zimelidine (100, 200 or 300 mg, p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine and alcohol combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study: 29192240

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 17
Study: 26883950

Group type: EXPERIMENTAL
Intervention: 40 International Units oxytocin once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 32
Study: 25764160

Group type: EXPERIMENTAL
Intervention: Immunotherapy with pegylated IFN‐α (subcutaneously weekly)
Number of subjects: 17
Study: 23846820

Group type: EXPERIMENTAL
Intervention: Combination of low‐dose spironolactone (50 mg/d) and metformin (1000 mg/d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Metformin (1000 mg/d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Low‐dose spironolactone (50 mg/d)
Number of subjects: 198
Study: 20618506

Group type: EXPERIMENTAL
Intervention: Intravenous siplizumab (0.012 mg/kg and 0.04 mg/kg every 2 weeks for 8 doses)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Subcutaneous siplizumab (5 mg x 12 weeks, 5 mg x 6 weeks + placebo x 6 weeks, 7 mg x 4 weeks + placebo x 8 weeks)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo (for both I.V. and S.C. studies)
Number of subjects: 544
Study: 18251761

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg (S100)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg (S50)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio) vs Salmeterol 100 (S100)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salmeterol 100 (S100)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio)
Number of subjects: 32
Study: 15918199

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 48
Study: 12744899

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV) conjugated to outer membrane protein of Neisseria meningitidis serogroup b, administered at 2, 4, 6, and 12 months of age.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (32 infants not given PCV).
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV) after the 12 month dose.
Number of subjects: 49
Study: 10567989

Group type: EXPERIMENTAL
Intervention: Endonasal shower (Siemens und Co, Bad Ems, Germany)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sterilized solution (Rhinomer, Zyma SA, Nyon, France)
Number of subjects: 80
Study: 9117049

Group type: EXPERIMENTAL
Intervention: Active antibiotic pastille
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1769828

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study: 7114439

Group type: EXPERIMENTAL
Intervention: Modified adult circle system with Latexspiral tubing of 110 cm total length and internal diameter 10.5 mm, and a 'Y' piece with a small dead space.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified adult circle system with Latexspiral tubing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kuhn- and Paedi-systems
Number of subjects: 0
Study: 31867641

Group type: EXPERIMENTAL
Intervention: VLNC standard information
Number of subjects: 1712

Group type: COMPARATOR
Intervention: No information about VLNC standard
Number of subjects: 1712
Study: 28628684

Group type: EXPERIMENTAL
Intervention: Two treatment sessions using BodyFX bipolar RF device
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Three treatment sessions using BodyFX bipolar RF device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Eight weekly sessions using BodyFX bipolar RF device
Number of subjects: 8
Study: 26116801

Group type: EXPERIMENTAL
Intervention: 1 × 10^7 MSCs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 3 × 10^7 MSCs
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 9 × 10^7 MSCs
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 24225174

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Reappraisal training
Number of subjects: 129

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 129
Study: 21474905

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 67
Study: 19117319

Group type: EXPERIMENTAL
Intervention: Staphylococcal superantigen (SAg)‐specific IgE in adenoid tissue
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Staphylococcal superantigen (SAg)‐specific IgE in tonsil tissues
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Staphylococcal superantigen (SAg)‐specific IgE in serum
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: High SEA levels
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation between SAg-specific IgE levels and tryptase levels
Number of subjects: 40
Study: 18084976

Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Number of subjects: 0
Study: 15526805

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 11247319

Group type: EXPERIMENTAL
Intervention: i.v. pamidronate (at 3-month intervals)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9439085

Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Naratriptan 0.25 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Naratriptan 0.1 mg
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: All doses of Naratriptan
Number of subjects: 613
Study: 8502260

Group type: EXPERIMENTAL
Intervention: Synthetic human growth hormone (Protropin)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 3551212

Group type: EXPERIMENTAL
Intervention: Prostacyclin (8.5 ng/kg/min for an average of 64 hours)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 28901118

Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) 3 times/week for 8 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard rehabilitation (SR) including physiotherapy sessions/telephone contact 1/week and writing home exercise logs
Number of subjects: 41
Study: 27388361

Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate (CHG) in 70% alcohol
Number of subjects: 920

Group type: COMPARATOR
Intervention: 0.5% chlorhexidine gluconate (CHG) in aqueous solution
Number of subjects: 920
Study: 23873319

Group type: EXPERIMENTAL
Intervention: Group 1: 550 μg fluoride (F)/g, pH 4.5
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group 2: 1,100 μg F/g, pH 7.0
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group 3: 550 μg F/g, pH 7.0
Number of subjects: 48
Study: 21610009

Group type: EXPERIMENTAL
Intervention: Self-determined motivation
Number of subjects: 175

Group type: COMPARATOR
Intervention: Non-progressors
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Regular exercise at six months
Number of subjects: 175
Study: 20103775

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 U of oral vitamin D2 at baseline and 10 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 100